Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Provided By PR Newswire
Last update: May 27, 2025
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026
Read more at prnewswire.com230.01
-1.79 (-0.77%)
1.57
+0.03 (+1.95%)
Find more stocks in the Stock Screener
